We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

Imagine being able to pop a few capsules in your mouth and be protected from bleeds the way infusions now do. That’s the goal of investigators in the Cockrell School of Engineering at The University of Texas at Austin.

The new oral delivery system uses micro- and nanoparticles to carry a protein therapy that treats hemophilia B, or factor IX deficiency. The findings were published in the November 30 issue of the International Journal of Pharmaceutics.

Researchers Report Oral FIX Delivery Breakthrough

Imagine being able to pop a few capsules in your mouth and be protected from bleeds the way infusions now do.

Octapharma Announces Two New Clinical Trials

WILATE®, a human-derived von Willebrand factor/coagulation factor VIII therapy, will be used in two upcoming clinical trials slated to launch in December 2016.

World AIDS Day Observance to Honor Hemophilia Community

The hemophilia community will be honored with the Thom Weyand Unsung Hero Award for its activism during the HIV/AIDS crisis.

Octapharma Announces Two New Clinical Trials

WILATE®, a human-derived von Willebrand factor/coagulation factor VIII therapy, will be used in two upcoming clinical trials slated to launch in December 2016.

Subscribe to Our Newsletter

 

 


Advertisements